RU2018131377A3 - - Google Patents

Download PDF

Info

Publication number
RU2018131377A3
RU2018131377A3 RU2018131377A RU2018131377A RU2018131377A3 RU 2018131377 A3 RU2018131377 A3 RU 2018131377A3 RU 2018131377 A RU2018131377 A RU 2018131377A RU 2018131377 A RU2018131377 A RU 2018131377A RU 2018131377 A3 RU2018131377 A3 RU 2018131377A3
Authority
RU
Russia
Application number
RU2018131377A
Other versions
RU2018131377A (ru
RU2740849C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018131377A publication Critical patent/RU2018131377A/ru
Publication of RU2018131377A3 publication Critical patent/RU2018131377A3/ru
Application granted granted Critical
Publication of RU2740849C2 publication Critical patent/RU2740849C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018131377A 2016-02-15 2017-02-14 Способ, включающий фиксированное дробное дозирование цедираниба RU2740849C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
US62/295,421 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Publications (3)

Publication Number Publication Date
RU2018131377A RU2018131377A (ru) 2020-03-17
RU2018131377A3 true RU2018131377A3 (ru) 2020-06-02
RU2740849C2 RU2740849C2 (ru) 2021-01-21

Family

ID=59625551

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018131377A RU2740849C2 (ru) 2016-02-15 2017-02-14 Способ, включающий фиксированное дробное дозирование цедираниба

Country Status (16)

Country Link
US (1) US20210322415A1 (ru)
EP (2) EP3417294B8 (ru)
JP (2) JP6865762B2 (ru)
KR (1) KR20180125456A (ru)
CN (1) CN109073650A (ru)
AU (1) AU2017221268B2 (ru)
CA (1) CA3014674A1 (ru)
DK (1) DK3417294T3 (ru)
ES (1) ES2906813T3 (ru)
HU (1) HUE058114T2 (ru)
MA (1) MA44251A (ru)
MX (2) MX2018009867A (ru)
PL (1) PL3417294T3 (ru)
RU (1) RU2740849C2 (ru)
TW (1) TWI827530B (ru)
WO (1) WO2017142871A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520921A (ja) 2017-05-18 2020-07-16 テサロ, インコーポレイテッド 癌を処置する併用療法
AU2018338901A1 (en) 2017-09-30 2020-05-07 Tesaro, Inc. Combination therapies for treating cancer
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (ru) 2000-06-06 2005-10-17 Астразенека Аб Хиназолиновые производные для лечения опухолей и фармацевтическая композиция
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
AU2005288736B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Cancer combination therapy comprising AZD2171 and imatinib
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
AU2009215375A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
MX2011008221A (es) * 2009-02-04 2011-08-17 Bipar Sciences Inc Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
JP6114296B2 (ja) * 2011-11-08 2017-04-12 インテリカイン, エルエルシー 複数の医薬品を使用した治療レジメン
AU2013261267B2 (en) * 2012-05-18 2017-06-29 Sumitomo Pharma Co., Ltd. Carboxylic acid compounds
CN114920840A (zh) * 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途

Also Published As

Publication number Publication date
DK3417294T3 (da) 2022-02-21
RU2018131377A (ru) 2020-03-17
TW201906610A (zh) 2019-02-16
CA3014674A1 (en) 2017-08-24
US20210322415A1 (en) 2021-10-21
HUE058114T2 (hu) 2022-07-28
WO2017142871A1 (en) 2017-08-24
JP2021105039A (ja) 2021-07-26
WO2017142871A8 (en) 2018-06-14
EP3417294B8 (en) 2022-05-04
PL3417294T3 (pl) 2022-05-09
AU2017221268B2 (en) 2024-02-15
JP6865762B2 (ja) 2021-04-28
RU2740849C2 (ru) 2021-01-21
JP2019504860A (ja) 2019-02-21
EP4071174A1 (en) 2022-10-12
EP3417294B1 (en) 2021-12-01
CN109073650A (zh) 2018-12-21
MX2018009867A (es) 2019-05-27
EP3417294A1 (en) 2018-12-26
MX2023007826A (es) 2023-07-07
ES2906813T3 (es) 2022-04-20
JP7271594B2 (ja) 2023-05-11
KR20180125456A (ko) 2018-11-23
TWI827530B (zh) 2024-01-01
EP3417294A4 (en) 2019-08-14
AU2017221268A1 (en) 2018-08-30
MA44251A (fr) 2018-12-26

Similar Documents

Publication Publication Date Title
JP2016154546A5 (ru)
JP1591073S (ru)
JP1583050S (ru)
RU2018131377A3 (ru)
BR112019009203A2 (ru)
BR122022012817A2 (ru)
CN303579138S (ru)
CN303676867S (ru)
CN303585182S (ru)
CN303584881S (ru)
CN303579306S (ru)
CN303579182S (ru)
CN303680030S (ru)
CN303573603S (ru)
CN303572923S (ru)
CN303569853S (ru)
CN303567786S (ru)
CN303566511S (ru)
CN303564787S (ru)
CN303677231S (ru)
CN303677892S (ru)
CN303591883S (ru)
CN303662339S (ru)
CN303636840S (ru)
CN303612258S (ru)